We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02450851
Recruitment Status : Recruiting
First Posted : May 21, 2015
Last Update Posted : June 2, 2023
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )

Brief Summary:

Background:

- Without an explanation for severe and sometimes life-threatening symptoms, patients and their families are left in a state of unknown. The NIH helped create a network of medical research centers, called the Undiagnosed Diseases Network (UDN), to provide care and answers for these individuals.

Objectives:

- To improve diagnosis and care for people with undiagnosed diseases.

Eligibility:

- People with undiagnosed diseases, and their relatives.

Design:

  • Participants will travel to one of the UDN medical centers for a 5-day clinical and research visit.

    • As part of the visit, UDN healthcare providers may ask participants to have:

      • Clinically indicated tests and procedures performed including:

        • A physical exam
        • Blood and urine tests
        • A review of health and family history
        • X-rays and body scans
        • Surveys
        • Photographs of the face and body
        • A special diet to see if the body can handle the food without having a reaction, like vomiting
        • Video or voice recordings
        • Other tests and procedures to help reach a diagnosis
      • Research tests and procedures performed including:

        • A skin biopsy. For this, a small piece of skin will be taken.
        • Surveys
        • Other tests and procedures for research that may not be related to a diagnosis or treatment.
  • Most participants will be asked to give samples for genetic testing.
  • Participants may be contacted after their visit to discuss test results. They may also be contacted in the future for interviews and surveys.
  • Relatives of participants may be asked to give samples for genetic testing. They may be asked to have parts of their visit recorded and to have additional tests. They may also be contacted in the future for interviews and surveys.
  • Clinical and research information collected will be stored in a database.
  • Information and samples collected will be shared with others for research purposes....

Condition or disease
Genetic Disease

Detailed Description:
Without an explanation for severe and sometimes life-threatening symptoms, patients and their families are left in a state of unknown. Many individuals find themselves being passed from physician to physician, undergoing countless and often repetitive tests in the hopes of finding answers and insight about what the future may hold. This long and arduous journey to find a diagnosis does not end for many patients- the Office of Rare Diseases Research (ORDR) notes that 6% of individuals seeking their assistance have an undiagnosed disorder. In 2008, the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP) was established with the goal of providing care and answers for these individuals with mysterious conditions who have long eluded diagnosis. The NIH UDP is a joint venture of the NIH ORDR, the National Human Genome Research Institute Intramural Research Program (NHGRI-IRP), and the NIH Clinical Research Center (CRC). The goals of the NIH UDP are to: (1) provide answers for patients with undiagnosed diseases; (2) generate new knowledge about disease mechanisms; (3) assess the application of new approaches to phenotyping and the use of genomic technologies; and (4) identify potential therapeutic targets, if possible. Prior to formation of the Undiagnosed Diseases Network (UDN), the UDP had evaluated 3300 medical records, admitted 750 individuals with rare and undiagnosed conditions to the NIH Clinical Center, and identified more than 70 rare disease diagnoses and several new conditions. The success of the NIH UDP prompted the NIH Common Fund to support the establishment of a network of medical research centers, the UDN, for fiscal years 2013-2022. The clinical sites perform extensive phenotyping, genetic analyses, and functional studies of potential disease-causing variants. The testing performed on patients involves medically indicated studies intended to help reach a diagnosis, as well as research investigations that include a skin biopsy, blood draws, and DNA analysis. In addition, the UDN is furthering the goals of the UDP by permitting the sharing of personally identifiable phenotypic and genotypic information within the network. By sharing participant information and encouraging collaboration, the UDN hopes to improve the understanding of rare conditions and advance the diagnostic process and care for individuals with undiagnosed diseases.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 16000 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Clinical and Genetic Evaluation of Patients With Undiagnosed Disorders Through the Undiagnosed Diseases Network
Actual Study Start Date : September 16, 2015
Estimated Primary Completion Date : December 31, 2028
Estimated Study Completion Date : December 31, 2028

Group/Cohort
Undiagnosed disorders
Patients with rare, undiagnosed disorders.



Primary Outcome Measures :
  1. Improve the level of diagnosis and care for patients with undiagnosed diseases through the development of common and site-specific protocols designed by an enlarged community of investigators [ Time Frame: Inpatient stay Day 1-5 and followup ]
    Improve the level of diagnosis and care for patients with undiagnosed diseases through the development of common and site-specific protocols designed by an enlarged community of investigators.

  2. Facilitate research into the etiology of undiagnosed diseases, by collecting and sharing standardized, high-quality clinical and laboratory data including genotyping, phenotyping, and documentation of environmental exposures [ Time Frame: Inpatient stay Day 1-5 and followup ]
    Facilitate research into the etiology of undiagnosed diseases, by collecting and sharing standardized, high-quality clinical and laboratory data including genotyping, phenotyping, and documentation of environmental exposures.

  3. Create an integrated and collaborative research community across multiple clinical sites and between laboratory and clinical investigators prepared to investigate the pathophysiology of these new and rare diseases, the impact of the diagnostic p... [ Time Frame: Inpatient stay Day 1-5 and followup ]
    Create an integrated and collaborative research community across multiple clinical sites and between laboratory and clinical investigators prepared to investigate the pathophysiology of these new and rare diseases, the impact of the diagnostic process on patients and families, and share this understanding to identify improved options for optimal patient management.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 100 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Individuals with undiagnosed conditions
Criteria
  • INCLUSION CRITERIA:
  • Ideal applicants to the UDN include individuals with:

    • One or more objective findings pertinent to the phenotype for which a UDN application was submitted.
    • No diagnosis despite evaluation by at least two specialists who assessed the patient for the objective finding(s).
    • Agreement for the storage and sharing of information and biomaterials, in an identified fashion amongst the UDN centers, and in a de-identified fashion to research sites beyond the network.
  • Applicants unable to consent can be enrolled.

EXCLUSION CRITERIA:

-Applicants who are unlikely to be accepted include individuals with:

  • Reported symptoms with no relevant objective findings.
  • A diagnosis explaining objective findings.
  • A diagnosis suggested on record review.
  • Unwillingness to share data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02450851


Contacts
Layout table for location contacts
Contact: Paul Mazur (844) 746-4836 paul_mazur@hms.harvard.edu

Locations
Show Show 24 study locations
Sponsors and Collaborators
National Human Genome Research Institute (NHGRI)
Investigators
Layout table for investigator information
Principal Investigator: William A Gahl, M.D. National Human Genome Research Institute (NHGRI)
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Human Genome Research Institute (NHGRI)
ClinicalTrials.gov Identifier: NCT02450851    
Other Study ID Numbers: 150130
15-HG-0130
First Posted: May 21, 2015    Key Record Dates
Last Update Posted: June 2, 2023
Last Verified: May 26, 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) ):
Rare Diseases
Undiagnosed Diseases
Natural History
Additional relevant MeSH terms:
Layout table for MeSH terms
Genetic Diseases, Inborn
Undiagnosed Diseases
Disease Attributes
Pathologic Processes